NCT05286528

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Retrospective, Non-interventional Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,484 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed. Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines

Conditions

• Chronic Myeloid Leukaemia

Interventions

Type	Name	Description
DRUG	Bosutinib	Bosutinib as prescribed in real world
DRUG	Imatinib	Imatinib as prescribed in real world
DRUG	Nilotinib	Nilotinib as prescribed in real world
DRUG	Dasatinib	Dasatinib as prescribed in real world
DRUG	Ponatinib	Ponatinib as prescribed in real world

Timeline

• Start date: 2020-11-18
• Primary completion: 2022-01-31
• Completion: 2022-01-31
• First posted: 2022-03-18
• Last updated: 2023-10-27
• Results posted: 2023-10-27

Locations

1 site across 1 country: Hungary